禽流感病毒ELISA快速检测试剂盒的研制及其重组核蛋白粘膜免疫研究
|
摘要
禽流感(AI)是由A型流感病毒引起的一种禽类的烈性传染病。自1878年意大利首先发现至今,世界各地都有特定毒株引起的禽流感爆发和流行,导致禽类的大量死亡和生产性能的急剧下降,造成了巨大的经济损失。目前,高致病性禽流感(HPAI)是国际兽疫局规定的A类动物传染病。近年来,禽流感的发生与流行,在我国已造成了巨大的经济损失和严重的社会影响,尤其是香港1997年和东南亚2003-2004年出现的禽流感病毒(AIV)直接感染并致死人的事件,已引了世人的震惊和关注。其防制已直接关系到我国养禽业的持续稳定发展和人民的身体健康。本研究主要是建立一种快速的检测禽流感病毒抗原的ELISA方法,弥补其它检测方法的不足,为该病的早期诊断提供可靠依据和技术保证;另外,由于禽流感病毒亚型之多,不同亚型之间无交叉保护作用,给该病的防制带来了极大的困难,鉴于此,本研究试图利用霍乱毒素B亚基(Cholera toxin B subunit, CTB)强有力的粘膜免疫佐剂作用,将禽流感病毒型特异性NP基因的表达产物与CTB混合或与CTB融合表达后,制成疫苗通过鼻腔粘膜免疫鸡,以期提高鸡体鼻腔、气管粘膜表面sIgA的含量,从而达到预防和控制禽流感的目的。主要研究工作和结果如下:
1.鸡抗AIV、兔抗AIV和山羊抗兔IgG高免血清的制备及山羊抗兔IgG的HRP标记
将H9N2亚型的AIV经9-11日龄鸡胚传代后,收获鸡胚尿囊液,经30,000r/m离心1h后,AIV沉淀用原尿囊液1/30倍体积的0.01mol/L,pH7.2的PBS重悬,所得悬液与福氏佐剂乳化后免疫鸡和兔,得到鸡抗AIV和兔抗AIV的高免血清,其琼扩效价均达到1:64;同时,以纯化的兔IgG免疫山羊,将获得的山羊抗兔IgG高免血清(1:64)纯化后,经辣根过氧化物酶(HRP)标记山羊抗兔IgG,制备出特异性强、免疫学活性和催化活性高的山羊抗兔IgG-HKP,且工作浓度高达1:4000,为禽流感的夹心ELISA诊断方法的建立奠定了坚实的物质基础。
2.检测禽流感病毒的酶联免疫吸附试验(ELISA)方法的建立
以纯化的鸡抗AIV IgG为包被抗体,兔抗AIV IgG为第二抗体,通过ELISA反应条件的优化选择,建立了检测AIV抗原的夹心ELISA法。结果表明,鸡抗AIV IgG的最佳包被浓度为1μg/mL,兔抗AIV IgG的最适工作浓度为5μg/mL;对已知的阳性样品,用夹心ELISA法测得的病毒滴度比血球凝集滴度高16倍以上,且能检出其它亚型的禽流感病毒;与新城疫病毒、传染性支气管炎病毒、减蛋综合征病毒、传染性喉气管炎病毒、传染性法氏囊病病毒、鸡痘病毒、马立克氏病病毒等无交叉反应,说明该方法有很高的特异性和敏感性。对14个鸡场送检的患有呼吸道疾病或有腹膜炎、眼炎、产蛋下降、怀疑为禽流感感染的病鸡进行了检测,结果有7个鸡场为阳性。
Avian Influenza (AT) is one of fatal infectious disease caused by influenza A virus in avian. It first appeared in Italy more than 100 years ago(around 1878), and, so far, different strains were found and caused important economic losses in the avian industry throughout the world. At present, highly pathogenic avian influenza (HPAI) is listed in A infectious diseases by World Organization for Animal Health(OIE). Recently, AI has produced important economic losses and bad effect to society in our country, especially, events that AI infected human being happened in Hongkong(1997) and south-eastern Asian (2003-2004), which shocked mankind and caused our attention to commonality sanitation of AI. A common viewpoint is that prevention of AI is closely linked to persistent and steady development of avian industry and humankind's health. This research is aimed to develop ELISA for detection of AIV in order to provide technique to forepart diagnoses of AI. In addition, Because of negligible cross-protection against different AIV subtypes, it is very difficuly to prevent avian influenza from outbreaking. Therefore, we attempted to mix or fused expression product of Cholera toxin B subunit(CTB), a strong mucosal immunization adjuvant, with NP, a expression product of nucleoprotein(NP) of AIV, then chicken were immunized with mixture(CTB+NP) and fused product(CTB-NP) by nasal cavity in order to enhance secretory IgA(sIgA) titer of nasal cavity and trachea surface, which maybe control and prevent AI from happening. The results of research are summarized as following:1. Preparation of sera of chicken anti-AIV, rabbit anti-AIV, goat anti-rabbit IgG and goat anti-rabbit IgG-HRPAIV (H9N2) was inoculated into 9 to 10-day embryonating chicken eggs by the allantoic route, then allantoic fluid was harvested and centrifuged with 30,000r/m, and AIV deposit was redissolved by 0.01mol/L PBS (pH7.2)which is 1/30 volume of allantoic fluid. Chicken and rabbits were immunized with redissolved fluid of AIV emulsified with Frund's adjuvant, and sera of chicken anti-AIV, rabbit anti-AIV were acquired after three inoculations, and the titers of AGED reach 1:64. At the same time, purified serum of goat anti-rabbit IgG(AGID: 1:64) from goat immunized with purified rabbit IgG was labeled with horseradish peroxidase(HRP). The conjugate is characteristic of high activity of immunity and its work concentration reached 1:4000. This laid a foundation for the development of sandwich enzyme-linked immunosorbent assay (ELISA) for AIV.
2. Development of enzyme-linked immunosorbent assay (ELISA) for AIV.A sandwich ELISA for detection of AIV antigen was developed by using purified chicken anti-ATV IgG as the first antibody coated on the ELISA plate and rabbit anti-AIV IgG regarded as the second antibody. The results showed that the optimum working concentration of chicken anti-AIV IgG and rabbits anti-AIV IgG were lug/mL and 5ug/mL, respectively. The dilution titers of positive AIV sample by ELISA was 16 times higher than that by hemagglutination test, and other AIV subtypes can also be detected by this method. No cross reaction was observed with Newcastle disease virus (NDV), infectious bronchitis virus (IBV), eggs drop syndrome virus (EDS^V), infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV), avian pox virus (APV) and Marek's disease virus(MDV). 7 of 14 suspicious chicken groups showing respiratory tract syndrome or peritonitis, opthalmitis, egg drop were positive detected by this method.3. Development and Application of Sandwich Enzyme-linked Immunosorbent AssayTest Kit for Detecting Avian Influenza Virus AntigenA Sandwich Enzyme-linked immunosobent assay test kit based on previous work was developed for detection of avian influenza virus (ATV) antigen. The kit consists of eleven reagents and a piece of 16-well microtiter plate. There were highly specificity, sensitivity and repeatability in detecting AIV antigen with the kit. It was stable well when storing at below -lO'C for six months. It is very easy to manipulate and the result can be reported within 3 hours. So far, different subtype ATVs including H5 and H9 subtypes from chicken and H5 subtype from Landes Goose were isolated from some provinces such as Hubei, Anhui and Henan and so on detected by the kit.4. Gene fusion and expression of nucleoprotein (NP) of AIV and the Cholera toxin B subunit (CTB)Vector pGEX-KG-CTB expressing CTB gene was developed after CTB gene was cloned into expression vector pGEX-KG containing GST gene. Then NP gene was cloned into the downstream of CTB gene in pGEX-KG-CTB, and the expression vector pGEX-KGCN was constructed. After correct cloning sites and sequences were indentified, CTB and CTB-NP were expressed in Escherichia coli BL21 (codon plus) strain, The results of SDS-PAGE showed that molecular weight of GST-CTB and GST-CTB-NP were about 38.0kD and 94.0kD, respectively; which matches the expected molecular weight. Western blotting showed NP protein in GST-CTB-NP takes on strong biological activity.
5. Mucosal immunization study on recombinant nucleoprotein of AIV45 chickens, 15 days old, were divided randomly into 5 groups at the start of experiments. Groups of 9 animals were immunized with NP, or NP+CTB, or CTB-NP, or CTB, at fhe same time, a group was control. All immunizations were given in nasal cavity for three times at 10-day intervals. Before every immunization and 10 days after the last immunization, sera, nasal wash, trachea wash and gut wash were collected for ELISA detection for corresponding immunoglobulin(IgG-NP, IgA-NP, slgA-NP). The results showed that high level IgG-NP and low level IgA-NP in sera happened. SlgA-NP antibody responses(day20 and day30) in nasal wash, trachea wash and gut wash were enhanced significantly by CTB(p<0.05). At day 30, ODs of slgA-NP in nasal wash and gut wash was significantly enhanced by CTB(CTB-NP group > CTB+NP group > NP group), and the difference were significant with each other(p<0.05). In all trachea wash, there was no difference(p>0.05) between CTB-NP group and CTB+NP group, but there was significantly difference(p>0.05)between the two groups and NP group; hi conclusion, when mixed with or fused expression product of recombinant NP, CTB was a candidate adjuvant for enhancing mucosal immunization of recombinant nucleoprotein of AIV.
1.鸡抗AIV、兔抗AIV和山羊抗兔IgG高免血清的制备及山羊抗兔IgG的HRP标记
将H9N2亚型的AIV经9-11日龄鸡胚传代后,收获鸡胚尿囊液,经30,000r/m离心1h后,AIV沉淀用原尿囊液1/30倍体积的0.01mol/L,pH7.2的PBS重悬,所得悬液与福氏佐剂乳化后免疫鸡和兔,得到鸡抗AIV和兔抗AIV的高免血清,其琼扩效价均达到1:64;同时,以纯化的兔IgG免疫山羊,将获得的山羊抗兔IgG高免血清(1:64)纯化后,经辣根过氧化物酶(HRP)标记山羊抗兔IgG,制备出特异性强、免疫学活性和催化活性高的山羊抗兔IgG-HKP,且工作浓度高达1:4000,为禽流感的夹心ELISA诊断方法的建立奠定了坚实的物质基础。
2.检测禽流感病毒的酶联免疫吸附试验(ELISA)方法的建立
以纯化的鸡抗AIV IgG为包被抗体,兔抗AIV IgG为第二抗体,通过ELISA反应条件的优化选择,建立了检测AIV抗原的夹心ELISA法。结果表明,鸡抗AIV IgG的最佳包被浓度为1μg/mL,兔抗AIV IgG的最适工作浓度为5μg/mL;对已知的阳性样品,用夹心ELISA法测得的病毒滴度比血球凝集滴度高16倍以上,且能检出其它亚型的禽流感病毒;与新城疫病毒、传染性支气管炎病毒、减蛋综合征病毒、传染性喉气管炎病毒、传染性法氏囊病病毒、鸡痘病毒、马立克氏病病毒等无交叉反应,说明该方法有很高的特异性和敏感性。对14个鸡场送检的患有呼吸道疾病或有腹膜炎、眼炎、产蛋下降、怀疑为禽流感感染的病鸡进行了检测,结果有7个鸡场为阳性。
Avian Influenza (AT) is one of fatal infectious disease caused by influenza A virus in avian. It first appeared in Italy more than 100 years ago(around 1878), and, so far, different strains were found and caused important economic losses in the avian industry throughout the world. At present, highly pathogenic avian influenza (HPAI) is listed in A infectious diseases by World Organization for Animal Health(OIE). Recently, AI has produced important economic losses and bad effect to society in our country, especially, events that AI infected human being happened in Hongkong(1997) and south-eastern Asian (2003-2004), which shocked mankind and caused our attention to commonality sanitation of AI. A common viewpoint is that prevention of AI is closely linked to persistent and steady development of avian industry and humankind's health. This research is aimed to develop ELISA for detection of AIV in order to provide technique to forepart diagnoses of AI. In addition, Because of negligible cross-protection against different AIV subtypes, it is very difficuly to prevent avian influenza from outbreaking. Therefore, we attempted to mix or fused expression product of Cholera toxin B subunit(CTB), a strong mucosal immunization adjuvant, with NP, a expression product of nucleoprotein(NP) of AIV, then chicken were immunized with mixture(CTB+NP) and fused product(CTB-NP) by nasal cavity in order to enhance secretory IgA(sIgA) titer of nasal cavity and trachea surface, which maybe control and prevent AI from happening. The results of research are summarized as following:1. Preparation of sera of chicken anti-AIV, rabbit anti-AIV, goat anti-rabbit IgG and goat anti-rabbit IgG-HRPAIV (H9N2) was inoculated into 9 to 10-day embryonating chicken eggs by the allantoic route, then allantoic fluid was harvested and centrifuged with 30,000r/m, and AIV deposit was redissolved by 0.01mol/L PBS (pH7.2)which is 1/30 volume of allantoic fluid. Chicken and rabbits were immunized with redissolved fluid of AIV emulsified with Frund's adjuvant, and sera of chicken anti-AIV, rabbit anti-AIV were acquired after three inoculations, and the titers of AGED reach 1:64. At the same time, purified serum of goat anti-rabbit IgG(AGID: 1:64) from goat immunized with purified rabbit IgG was labeled with horseradish peroxidase(HRP). The conjugate is characteristic of high activity of immunity and its work concentration reached 1:4000. This laid a foundation for the development of sandwich enzyme-linked immunosorbent assay (ELISA) for AIV.
2. Development of enzyme-linked immunosorbent assay (ELISA) for AIV.A sandwich ELISA for detection of AIV antigen was developed by using purified chicken anti-ATV IgG as the first antibody coated on the ELISA plate and rabbit anti-AIV IgG regarded as the second antibody. The results showed that the optimum working concentration of chicken anti-AIV IgG and rabbits anti-AIV IgG were lug/mL and 5ug/mL, respectively. The dilution titers of positive AIV sample by ELISA was 16 times higher than that by hemagglutination test, and other AIV subtypes can also be detected by this method. No cross reaction was observed with Newcastle disease virus (NDV), infectious bronchitis virus (IBV), eggs drop syndrome virus (EDS^V), infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV), avian pox virus (APV) and Marek's disease virus(MDV). 7 of 14 suspicious chicken groups showing respiratory tract syndrome or peritonitis, opthalmitis, egg drop were positive detected by this method.3. Development and Application of Sandwich Enzyme-linked Immunosorbent AssayTest Kit for Detecting Avian Influenza Virus AntigenA Sandwich Enzyme-linked immunosobent assay test kit based on previous work was developed for detection of avian influenza virus (ATV) antigen. The kit consists of eleven reagents and a piece of 16-well microtiter plate. There were highly specificity, sensitivity and repeatability in detecting AIV antigen with the kit. It was stable well when storing at below -lO'C for six months. It is very easy to manipulate and the result can be reported within 3 hours. So far, different subtype ATVs including H5 and H9 subtypes from chicken and H5 subtype from Landes Goose were isolated from some provinces such as Hubei, Anhui and Henan and so on detected by the kit.4. Gene fusion and expression of nucleoprotein (NP) of AIV and the Cholera toxin B subunit (CTB)Vector pGEX-KG-CTB expressing CTB gene was developed after CTB gene was cloned into expression vector pGEX-KG containing GST gene. Then NP gene was cloned into the downstream of CTB gene in pGEX-KG-CTB, and the expression vector pGEX-KGCN was constructed. After correct cloning sites and sequences were indentified, CTB and CTB-NP were expressed in Escherichia coli BL21 (codon plus) strain, The results of SDS-PAGE showed that molecular weight of GST-CTB and GST-CTB-NP were about 38.0kD and 94.0kD, respectively; which matches the expected molecular weight. Western blotting showed NP protein in GST-CTB-NP takes on strong biological activity.
5. Mucosal immunization study on recombinant nucleoprotein of AIV45 chickens, 15 days old, were divided randomly into 5 groups at the start of experiments. Groups of 9 animals were immunized with NP, or NP+CTB, or CTB-NP, or CTB, at fhe same time, a group was control. All immunizations were given in nasal cavity for three times at 10-day intervals. Before every immunization and 10 days after the last immunization, sera, nasal wash, trachea wash and gut wash were collected for ELISA detection for corresponding immunoglobulin(IgG-NP, IgA-NP, slgA-NP). The results showed that high level IgG-NP and low level IgA-NP in sera happened. SlgA-NP antibody responses(day20 and day30) in nasal wash, trachea wash and gut wash were enhanced significantly by CTB(p<0.05). At day 30, ODs of slgA-NP in nasal wash and gut wash was significantly enhanced by CTB(CTB-NP group > CTB+NP group > NP group), and the difference were significant with each other(p<0.05). In all trachea wash, there was no difference(p>0.05) between CTB-NP group and CTB+NP group, but there was significantly difference(p>0.05)between the two groups and NP group; hi conclusion, when mixed with or fused expression product of recombinant NP, CTB was a candidate adjuvant for enhancing mucosal immunization of recombinant nucleoprotein of AIV.
引文
1.于康震,付朝阳,崔尚金,步志高,唐秀英.我国禽流感防制研究进展.中国兽医学报,2001,21(1):103-106
2.于康震,陈化兰,唐秀英.97香港禽流感.中国畜禽传染病,1998,20(3):187-191
3.于康震,崔尚金,付朝阳,唐秀英.禽流感与养禽业发展和人类健康.中国预防兽医学报,2000,22(4):312-315
4.马保华和毕英佐.IgA与粘膜免疫.辽宁畜牧兽医,1999,1:40-42
5.马思奇.粘膜免疫与未来的疫苗发展.中国畜禽传染病,1994,5:55-57
6.王恒安,王士强,严亚贤,吴祖立,华修国.鸭源禽流感病毒的分离与鉴定.江苏农业研究,1999,20(4):57-60
7.王锡坤,鞠复帮,王立南.禽流感琼脂扩散试验抗原制备方法的研究.中国畜禽传染病,1987,7(1):24-26
8.邓国华,唐秀英,田国斌.禽流感病毒重组核蛋白在琼扩诊断中的应用.中国预防兽医学报,2000,22(增刊):25-27
9.付朝阳,邢大昌,唐秀英,张亚非,于康震,冯菊艳.高致病力禽流感的流行与防制研究进展.中国预防兽医学报,2001,23(5):393-396
10.付朝阳,于康震,唐秀英,贾永清,冯菊艳,田国斌,吴东来.H9亚型禽流感油乳剂灭活苗免疫产生期内T淋巴细胞表型亚类的检测与研究.中国预防兽医学报,2001,23(6):430-433
11.甘孟侯主编.禽流感.北京:北京农业大学出版社,1995
12.甘孟侯主编.禽流感.第二版,北京:中国农业出版社,2002.
13.田国斌,赵增连,唐秀英,林祥梅,于康震,陈溥言.鸭源禽流感病毒的分离和鉴定.中国预防兽医学报,1999,21(1):1-3
14.田季德,徐兆炜,高庆申,刘延清.霍乱毒素B亚单位基因的克隆和表达.中国医学科学院学报,1991,13(5):332-337
15.石成华,曹诚,张京生,马清均.乙肝PreS2抗原决定簇和霍乱毒素B亚单位因的融合与表达.生物化学杂志,1994,10(5):533-538
16.刘明,于康震,崔尚金.RT-PCR快速诊断禽流感的研究.中国预防兽医学报,2000,22(增刊):176-179
17.刘泽文,徐涤平,杨峻,邵华斌,段正赢,山口成夫.应用逆转录套式PER检测禽流感病毒核酸研究.湖北农业科学,2003,4:90-92
18.朱立平,陈学清主编.免疫学常用实验方法.北京:人民军医出版社,2000
19.纪剑飞,张成刚.包涵体重组蛋白的纯化及复性,沈阳药科大学学报,1998,15(4):303-307
20.阴天榜,刘兴友等著.家禽免疫学.北京:中国农业出版社,1999
21.何志勇,李明峰,张惟杰,吴祥甫.霍乱毒素B亚单位基因(CtxB)的克隆及其表达.生物化学与生物物理学报,2000,32(2):149-152
22.何昭阳,胡桂学,王春风主编.动物免疫学实验技术.长春:吉林科学技术出版社,2002,59-61。
23.宋晓晖,王中力,陈西钊.禽流感诊断研究进展.中国动物检疫,2003,20(11):45-47
24.张庶民,祁自柏.基因工程表达蛋白包涵体的形成和纯化.微生物学免疫学进展,1995,23(1):52-54
25.张鹤晓,赖平安,刘环,刘继红,郭晋优,谷强,张利峰,汪琳,段生涛,朱文斯,杨伟,黄茜华,赖少梅,李宁.荧光RT-PCR方法检测活禽和禽组织中禽流感病毒的研究.检验检疫科学,2004,14(1):1-5
26.李自力,许青荣,毕丁仁,王桂枝,程峰.湖北省禽流感的诊断及病毒株的分离与初步鉴定中国预防兽医学报,2001,23(3):146-148
27.李海燕,于康震,辛晓光,秦运安,李雁冰.禽流感间接ELISA诊断试剂盒的研制及应用.中国预防兽医学报,2001,2(35):372-376
28.李海燕,辛晓光,田国斌,张晶,于康震.禽流感抗体斑点-ELISA诊断诊断技术的研究.中国预防兽医学报,1999,21(5):321-325
29.李海燕,辛晓光.禽流感病毒抗原成分免疫活性的分布研究.中国预防兽医学报,2000,22(增刊):94-97
30.杜念兴主编.兽医免疫学,第二版.北京:中国农业出版社,1997
31.沈关心,周汝麟主编.现代免疫学实验技术.武汉:湖北科学技术出版社,1998
32.肖运才,李自力,胡思顺,石德时,许青荣,程峰,刘梅,毕丁仁,王桂枝.禽流感病毒夹心ELISA快速检测方法的研究.畜牧兽医学报,2004,35(5):536-541
33.邱德新.猪繁殖与呼吸综合征(PRRS)和伪狂犬病ELISA抗体检测方法及PRRSV弱毒活疫苗研究.[博士论文].华中农业大学,2003
34.陈化兰,于康震,田国滨,唐秀英,卢景良.DNA免疫诱导鸡对禽流感病毒的免疫保护反应.中国农业科学,1998,31(5):63-68
35.陈化兰,于康震,田国滨,唐秀英,卢景良.禽流感病毒血凝素基因的克隆及其DNA疫苗的免疫原性.中国兽医学报,1997,17(6):555-558
36.陈化兰,于康震,张建林,田国彬,唐秀英.H7亚型禽流感病毒血凝素基因重组鸡痘病毒活载体疫苗免疫原性评估.中国预防兽医学报,2004,26(1):7-9
37.陈全娇.鸡源禽流感的分离鉴定及HA基因的克隆和表达.[硕士论文].华中农业大学,2003
38.陈吉祥,李广林,薛飞群,陈化兰,于康震,赵荣材.禽流感HA基因疫苗脂质体的制备及其理化性质,中国兽医学报,1999,19(3):230-232
39.陈伯伦,张泽纪,陈伟斌.禽流感研究Ⅰ.鸡A型禽流感病毒的分离和血清学初步鉴定.中国兽医杂志,1994,20(10):3-5
40.陈伯伦,张泽纪,陈伟斌.禽流感研究Ⅰ.鸡A型禽流感病毒的分离和血清学初步鉴定.中国兽医杂志,1994,20(10):3-5
41.陈绍熙,阚立抒,孙广力,赵春泰,邢秀珍,车有权.黑龙江省禽流感调查.中国畜禽传染病,1997,4:56-57
42.陈福勇,夏春.禽流感A/鸡/北京/1/96(H9N2)株核蛋白基因克隆和序列分析.中国预防兽医学报,1999,21(2):130-133
43.周元军.禽流感的防制与禽流感监测系统的建立.医学动物防制,2003,19(5):311-313
44.林纪胜.粘膜免疫的研究进展.中国人兽共患病杂志,1999,15(4):86-88
45.金奇主编.医学分子病毒学.北京:科学出版社,2001
46.柯岩,陈哲生.制各兔抗人IgG抗体的一种简便方法.微生物学通报.1997,24(5):315—317
47.赵增连,陈溥言,林祥梅,蔡宝祥.一种敏感的禽流感病毒快速定型双扩散法.中国兽医学报,1997,17(3):290-291
48.饶吉航,冉智光,苏承忠,蒋茹,胡友兰,汤明.鹌鹑H93亚型禽流感.中国兽医医杂,2004,40(2):56
49.凌明圣,许祥裕,丁树标.以包涵体形式存在的重组蛋白的纯化和体外折叠.中国生化药物杂志,1995,16(3):135-138
50.唐秀英,田国斌,于康震,冯菊艳.禽流感油乳剂灭活疫苗的研究.中国预防兽医学报,1999,21(6):401-405
51.唐秀英,田国斌,赵传删,周金法,于康震.中国禽流感流行株的分离鉴定.中国畜禽传染病,1998,20(1):1-5
52.唐建霞,王幼明,黄克和.实验性感染禽流感病毒抑制鸡的细胞免疫功能.江苏农业科学,2004(1):75-77
53.徐玉栋.粘膜DNA疫苗研究进展.国外医学口腔医学分册,2000,27(5):283-285
54.殷震,刘景华主编.动物病毒学.第二版.北京:科学出版社,1997
55.郭志儒和高宏伟.我国应尽快建立兽医与人医一体化的公共卫生体系.中国兽医学报,2004,24(3):209-211
56.郭建刚,李华明,刘棋,邹联斌,郑敏,邓朝阳.五种常用消毒剂对禽流感病毒的杀灭试验.广西畜牧兽医,2003,19(2):63-64
57.郭春祥和郭锡琼.介绍一种简单、快速、高效的辣根过氧化物酶标记抗体的过碘酸钠法.上海免疫学杂志,1983,3(2):97-100
58.顾云,张莉,大野尚仁.鼠和兔中流行性感冒病毒抗体的制备及测定.药物生物技术,2003,10(2):106
59.顾贫.区分口蹄疫免疫动物与野毒感染动物的鉴别诊断方法研究.[博士论文].华中农业大学,2003
60.高杰英.粘膜免疫向免疫学提出了新问题.上海免疫学杂志,2000,20(5):257-259
61.高致病性禽流感防治手册编写组编.高致病性禽流感防治手册.北京:中国农业出版社,2004:7-8
62.崔尚金,陈化兰,唐秀英,邓国华,田国斌,于康震.禽流感RT-PCR诊断法的建立.中国畜禽传染病,1998,20(2):105-107。
63.曹诚,马清均,石成华等.丙型肝炎病毒抗原决定簇与霍乱毒素B亚单位的融合表达及融合蛋白的抗原性.病毒学报,1995,11(2):99-106
64.黄庚明,辛朝安.PCR制备地高辛标记的探针检测禽流感病毒核酸.中国兽医杂志,2001,37(12):3-7
65.黄祯祥.医学病毒学基础及实验技术.北京:科学出版社,1990,661-671
66. Abraham A, Sivanandan V, Haivorson A, et al.. Standardization of enzyme-linked immunosorbent assay for avian influenza virus antibodies in turkeys. Am J Vet Res, 1986, 47(3): 561-566
67. Abraham A,Sivanandan V et al. Antigen-capture enzyme immunoassay for detection of avian influenza virus in turkeys. Am J Vet Res, 1993, 54(9): 1385-1390
68. Aitken R, Hirst T R, Recombinant enterotoxins as vaccine against Escherichia coli-mediated diarrhoea, Vaceine, 1993, 11: 227-233
69. Alexander D J, Lister S A,. Johnson M J, Randall C J, Thomas P J. An outbreak of highly pathogenic avian influenza in turkeys in Great Britain in 1991. Vet Rec, 1993, 132:535-536
70. Alexander D J. Current Situation of Avian Influenza in Poulry in Great Britain.. Proc. first International Symposium on Avian Influenza, 1986, 35-45.
71. Alexander D J. Report on Avian Influenza in the Eastern Hemisphere during 1997-2002. Avian Dis, 2003, 47:792-797
72. Bean W J. Correlation of influenza A virus nucleoprotein genes with host species. Hrology, 1984, 133(2): 438-442.
73. Beard C W. Avian influenza antibody detection by immunodissusion. Avian Dis, 1970, 14 (2):337-341
74. Bennink J R and Yewdell J W. Mttrine eytotoxic T lymphocyte recognition of individual influen-za virus proteins. High frequency of nonresponder MHC class Ⅰ alleles, J Exp Med, 1988, 168:1935—1939.
75. Beunink J R, Yewdell J W, Gerhard W. A viral polymerase involved in recognition of influenza virus-infected cells by a cytotoxie T-cell clone. Nature, 1982. 296:75—76.
76. Bennink J R, Yewdell J W, Smith G L, Moss B. Anti-influertzavirus cytotoxie T lymphocytes re-cognize the three viral polymerases and a nonstruetural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol, 1987, 61:1098-1102
77. Biswas S K., Boutz P, Nayak D P. Influenza Virus Nucleoprotein Interacts with Influenza Virus Polymerase Proteins. J Virol, 1998, 72(7): 5493-5501
78. Blanehard T G, Lycke N,. Czinn S J, Nedrud J G. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 1998, 93:22-27
79. Boyle D B, Selleck P, Heine H G. Vaccinating chickens against avian influenza with fowlpox recombinants expression the H7 haemagglutinin. Aust Vet J, 2000,78 (1): 44-48
80. Brown E G. Influenza virus genetics. Biomed & Pharmacother, 2000. 54:196-209
81. Buisch WW, Hall AE, Mcdaniel HA. 1985-1984 lethal avian influenza outbreak. Virology,1984, 146:963-973
82. Butler J E, Richardson H B, Swanson P A, Kopp W C, Suelzer M T. The influence of muramyl peptide on the secretory immune response. Annals of the New York Academy of science, 1983, 409:669-687
83.CalnekB W主编.高福,苏敬良主译.禽病学第十版,中国农业出版社,1999
84. Carnpen H, Easterday B C, Hinshaw V S, Van-Campen H. Destruction of lymphocytes by a virμLent avian influenza A virus. J Gen Virol, 1989a, 70:467-472
85. Campen H, Easterday B C, Hinshaw V S, Van-Campen H. Virulent avian influenza A viruses: their effect on avian lymphocytes and macrophages in vivo and in vitro. J Gen Virol, 1989b, 70: 2887-2895
86. Capua I, Alexander D J. Avian influenza and human health. Acta Trop, 2002, 83(1): 1-6
87. Chen Z, Li Y, Krug R M. Influenza A virus NSI protein targets poly(A)-binding protein Ⅱ of the cellar 3'-end processing machinery. EMBO J, 1999, 18:2273-2283
88. Christensen J P, Doherty P C, Branum K C, Riberdy J M. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8~+T cell memory. J Virol, 2000, 74:11690-11696
89. Claas E C J, de Jong J C, van Beck R. Human influenza virus A/Hongkong/156/97(H_5N_1 infection. Vaccine, 1998, 16(9/10): 977-978
90. Cleland J L and Wang D I C. Cosolvent effects on refolding and ggregation. ASC Syymposium Ser, 1993, 516:151-166
91. Clements J D, Hartxog N M, Lynon F L. Adjuvant activity of Escheriehia eoli heat labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine, 1988, 6:269-277
92. Czerkinsky C, Russell M W. Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun, 1989, 57(4): 1072-1077
93. Dallas W S and Falkow S. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin. Nature, 1980, 288(5790): 499-501
94. Davey J, Dimmock N J, Colman A. Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopns oocytes. Cell, 1985, 40 (3): 667-675.
95. de Geus B, Dol-Bosman M, Seholten J W, Stok W, Bianchi A. A comparison of natural and recombinant cholera toxin B subunit as stimμLatoryfactors in intranasal immunization. Vaccine, 1997, 15(10): 1110-1113
96. de Haan L, Verweij W R, Felt I K, Holtrop M, Hol W G J, Agsteribbe E, Wilsehut J. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology, 1998, 94(3): 424-430.
97. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun, 1997, 65(7): 2821-2828.
98. Dubenskey T W Jr, Liu M H ,ulmer J B. Delivery systems for gene-based vaccines. Mol Med, 2000,6(9): 723-732.
99. Elson C O, Ealding W. Generalised systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol, 1984, 132(6): 2736-2741
100. Erdile L F, Guy B. OspA lipoprotein of Borrelia burgdofferi is a mueosal immunogen and adjuvant. Vaccine, 1997, 15(9): 988-996
101. Fitch W M, Leiter J M, Li X Q, Palese P. Positive Darwinian evolution in human influenza A vi- ruses. Prec. Natl. Acad. Sci. USA, 1991, 88(10): 4270-4274.
102. Flo J, Goldman H, Roux M, Massouh E. Oral administration era bacterial immunomodulator enhances the immune response to cholera toxin. Vaccine, 1996, 14(12): 1167-1173
103. Frace A M, Klimov A I, Rowe T, Black R A, Katz J M. Modified M2 proteins produce heretotypic immunity against influenza A virus. Vaccine, 1999, 17:2237-2244.
104. Fukushima A, Yoo Y C, Yoshimatsu K, Matsuzawa K, Tamura M, Tono-oka S, Taniguchi K, Urasawa S, Arikawa J, Azuma I. Effect of MDP-LYS(L18)as a mueosal immtmoadjuvant on protection of mucosal infection by Sendai virus and rotavirus. Vaccine, 1996, 14(6): 485-491
105. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy D E, Durbin J E, Palese P, Muster T. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems, Virology, 1998, 252(2): 324-330
106. Garnett W H. Status of avian influenza in poulry: 1981-1986. In: Proceedings of the Second International Symposium on Avian influenza, 1987. University of Wisconsin, Madison, pp. 61-66.
107. Gelb J Jr, Nix W A, Gellman S D. Infectious bronchitis virus antibodies in tears and their relationship to immunity. Avian Dis, 1998, 42(2): 364-374
108. Gleeson M, Pyne D B. Exercise effects on mucosal immunity. Immunology and Cell Biology, 2000, 78:536-544
109. Gotch F, MeMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human eytotoxic T lymphocytes. J Exp Med, 1987,165(2):408-416
110. Gust I D, Hampson A W, Lavanchy D. Planning for the next pandemic of influenza. Rev Med Virol, 2001, 11(1): 59-70
111. Hajishengallis G, Hollingshead S K, Koga T, Russell M W. Mueosal Immunization with a Bacterial Protein Antigen genetically coupled to cholera toxin A2/B subunit. J Immun, 1995, 154(9): 4322-4332
112. Hannant D, Easeman R. I, Mumford J A. Mucosal vaccination with inactivated equine influenza virus stimulates neutralising antibody in that nasopharynx of horses. Vet Immunol Immunopathol, 1996, 54(3): 205-209
113. Hatada E, Saito S, Fukuda R. Mutant influenza viruses with a defective NS1 protein cannot bock the activation of PKR in infected cells. J Virol, 1999, 73(3): 2425-2433
114. Hayashida H, Toh H, Kikuno R, Miyata T. Evolution of influenza genes. Mol Biol Evol, 1985, 2(4): 289-303
115. Hazama M, Mayumi-Aono A, Miyazaki T, Hinuma S, Fujisawa Y. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, and B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology, 1993, 78(4): 643-649
116. Hinshaw V S, Olsen C W, Dybdahl-sissoko N, Evans D. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol,1994, 68(6): 3667-3673
117. Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature, 1981, 292(5822): 413-417
118. Inn H B. The epidemiology and evolution of influenza viruses in pigs. Vet Microbiol, 2000, 74(1-2): 29-46
119. Itakura K, Hirose T, Crea R, Riggs A D, Heynecker H, Bolivar F, Boyer H W. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin, Science, 1977, 198(4321): 1056-1063
120. Ito T, Gorman O T, Kawaoka Y, Bean W J, Webster R G, Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins, J Virol, 1991,65(10): 5491-5498.
121. Jameson J, Cruz J,. Ennis F A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol, 1998, 72(11): 8682-8689
122. Jayawardane G W L, Spradbrow P B. Mueosal immunity in chickens vaccinated with the V4 strain of Newcastle Disease virus. Vet Microbiol, 1995, 46(1-3): 69-77.
123. Johansson B E, Bucher D J, Kilbourne E D. Purified influenza virus hemagglutinin and neuramin- idase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol, 1989, 63(3): 1239-1246
124. Kawaoka Y, Chambers T M, Sladen W L, Webster R G, Is the gene pool of influenza viruses in shorebirds and gμLls different from that in wild ducks? Virology, 1988, 163(1): 247-250
125. Kawaoka Y, Gorman O T, Ito T, Wells K, Donis R O, Castmeei M R, Donatelli I, Webster R G.. Influence of host species on the evolution of the nonstmetural (NS) gene of influenza A viruses. Virus Res, 1998, 55(2): 143-156
126. Keller D, Koster F T, Marks D H, Hosbach P, Erdile L F, Mays J P. Safety and immunogenicity of a recombinant outer surface protein A lyme vaccine, JAMA, 1994, 271 (22): 1764-1768
127. Kodihaili S, Sivanandau V, Nagaraja K V, Shaw D, Halvorson DA. A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection. Vaccine, 1994,12(15): 1467-1472
128. Kodihaili S, Sivanandan V, Nagaraja KV, Goyal SM, Halvorson DA. Antigen-capture enzyme immunoassay for detection of avian influenza virus in turkeys. Am J Vet Res, 1993, 54(9): 1385-1390
129. Kuwano K, Scott M, Young J F, Ennis F A. HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response. J Immunol, 1988. 140(4):1264-1268
130. Kuwano K, Tamura M, Ennis F A. Cross-reactive protection against influenza A virus infections by an NSl-specifie CTL clone. Virology, 1990, 178(1): 174-179.
131. Lasley F A. Economies Of Avian Influenza: Control vs Noncontrol. In: Proceedings of the Second International Symposium on Avian Influenza, 1987. University of Wisconsin, Madison, pp.390-399.
132. Laudert E, Sivanandan V, Haivorson D. Effect of an H5Nlavian influenza virus infection on the immune system of mallard ducks. Avian Dis, 1993, 37(3): 845-850
133. Lee A and Chen M. Successful immunization against gastric infection with Helicobacter species: use era cholera toxin B-subunit-whole-cell vaccine, Infect Immun, 1994, 62(8): 3594-3597.
134. Levi R ,Amen R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine, 1996,14(1): 85-92.
135. Liang X P, Lamm M E, Nedrud J G.. Oral administration of cholera toxin-sendai virus conjugate potentiates gut and respiratory immunity against sendai virus. J Immunol, 1988, 141(5): 1495-1501
136. Lipscombe M, Charles I G, Roberts M, Dougan G, Tite J, Fairweather N F. Intranasal immunization using the B subunit of Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertusis P.69 antigen. Mol Microbiol, 1991.5(6): 1385-1392
137. Liu L M and MacPherson G G.. Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and prime naive T cells in rive. J Exp Med, 1993, 177(5): 1299-1305
138. Lovgren K, Kaberg H, Morein B. An experimental influenza subunit vaccine(iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous adminitration. Clin Exp Immunol, 1990, 82(3): 435-439
139. Lovgren K. the serum antibody response diatributed in subclass and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol, 1988, 27(2): 241-245
140. Lycke N and Hoimgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology, 1986, 59(2): 301-308
141. McGhee J R, Mestecky J, Dertzbaugh M T, Eldridge J H, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development.Vaccine, 1992, 10(2): 75-88
142. MeKENZIE S J and Halsey J F. Cholera Toxin B subunit As a Carrier Protein to Stimulate a Mucosal Immune Response. J Immunol, 1984, 133(4): 1818-1824
143. McNuly M S, Allan G M, Adair B M. Efficacy of avian influenza neuraminidase -specific vaccines in chickens. Avian Pathol, 1986, 15:107-115
144. Mestecky J. The common mucosal immune system and current strategies for induction of immune response in external secretions. J Clin Immunol, 1987, 7(4): 265-272
145. Michalek S M,Morisaki I, Gregory R I, Kiyono H,Hamada S,MeGhee J R . Oral adjuvant enhance IgA responses to Streptococcus rautans. Mol Immunol, 1983, 20(9): 1009-1018
146. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 1984, 308(5958): 457-460
147. Morein B. Iscoms. VetMicrobiol, 1990, 23(1-4): 79-84
148. Morein B.The iscom antigen-presenting system. Nature, 1988, 332(6161): 287-288
149. Morisaki I,Michalek S M, Harmon C C,Terii M, Hamada S, McGhee J R. Effective immunity to dental caries:enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants. Infect Immun, 1983, 40(2): 577-591
150. Mowat A M, Donaclaie A M, Reid G, Jarrett O. Immune-stimulating complexes containing QuilA and protein antigen prime class Ⅰ MHC-restrieted T lymphoeytes in vivo and are immunogenic by the oral route. Immunology, 1991, 72(3): 317-322
151. Mowat A M, Maloy K J, Donachie A M. Immune-stimμLating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology, 1993, 80: 527-534.
152. Murphy F A, Paul J, Marian C, Veterinary Virology (Third edition). Academic Press, New York, 1999, 459-468
153. Naeem K. The avian in(?)uenza H7N3 outbreak in South Central Asia. In: Proceedings of the 4th International Symposium on Avian Influenza, Athens, Georgia. US Animal Health Association, 1998, pp, 31-35
154. Nashar T O, Amin T, Mareello A, Hirst T R. Current progress in the development of the b-subunits of cholera-toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine, 1993.11 (2): 235-240
155. Nedrud J G, Liang X, Hague N, Lamm M E. Combined oral/nasal immunization protects mice from sendal virus infection. J Immunol,1987, 139(10): 3484-3492
156. Neirynek S, Derro T, Saelens X, et al. A universal influenza A vaccine based on the extraeellular domain of the M2 protein. Nat Med,1999,5(10): 1157-1163
157. Nemeroff M E, Barabino S M, Li Y, Keller W, Krug R M. Influenza virus NS1 protein interacts with the cellar 30 kDa subunit of CPSF and inhibits 3'-end formation of cellular pre-mRNAs. Mol Cell, 1998, 1(7): 991-1000
158. Neumann G, Castrucci M R, Kawaoka Y. Nuclear Import and Export of Influenza Virus Nucleoprotein. J Virol, 1997,71(12): 9690-9700
159. Nicholoson K G, Wood J M, Zambon M. Influenza. Lancet, 2003, 362(9397): 1733-1745
160. Nugent J, A Li Wan Po, Scott E M. Design and delivery of non-parenteral vaccines. J Clin Pharm Ther, 1998, 23(4): 257-285
161. O'Neill R E, Talon J, Palese P. The influenza virus NEP(NS2 protein)mediates the nuclear export of viral ribonucleoproteins. EMBO J, 1998, 17(1): 288-296
162. Ogra P, Leibovitz E, Zhao-Ri G. Oral immunization and secretory immunity to virus. Curr Top Microbiol Immunol, 1989, 146:73-81
163. Oka T, Honda T, Morokuma R, Ginnaga A, Ohkuma K, Sakoh M. Enhancing effects of pertusis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally. Vaccine, 1994, 12(14): 1255-1258
164. Parkin N ,Chiu P ,Coelingh K. Genetically engineered live attenuated influenza A virus vaccine candidates. J Virol, 1997, 71(4): 2772-2778
165. Parvin J D, Moscona A, Pan W T, Leider J M, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol, 1986, 59(2): 377-383.
166. Pavlovskis O R, Rollwagen F M, Rollins D M, Walker R I. Experimental oral camplyobacter vaeine. Vaccine, 1992, 10:290-295
167. Pertmer T M, Oran A E, Moser J M, Madorin C A, Robinson H L. DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nueleoprotein. J Virol, 2000, 74:7787-7793.
168. Philpott M, Easterday B C, Hinshaw V S. Neutralizing epitopes of the H5 hemagglutinin from a virulent avian influenza virus and their relationship to pathogenicity. J Virol, 1989, 63: 3453-3458
169. Qiao C L, Yu K Z ,Jiang Y P, Jia Y Q, Tian G B, Liu M, Deng G H, Wang X R, Meng Q W, Tang X Y. Protection of chickens against highlt lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol, 2003,32(1): 25-32.
170. Reay P A, Jones I M, Gotch F M, McMichael A J, Brownlee G G. Recognition of the PBI, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxie T lymphocytes. Virology, 1989, 170:477-485
171. Robert J, Eekroade D V M, Linda A. Avian Influenza in Pennsylvania—The Beginning. In: Proceedings of the Second International Symposium on Avian Influenza, University of Wisconsin, Madison, 1987, pp. 22-32
172. Rogers G N. and PaμLson J C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology, 1983, 127(2): 361-373
173. Rollwagen F M, Pacheco N D, Clements J D, Pavlovskis O R, Rollins D M, Walker R I. Killed campylobacter elicits immune-response and protection when administered with an oral adjuvant. Vaccine, 1993, 11(13): 1316-1320
174. Rott R, Becht H, Orlich M. The significance of influenza virus neuraminidase in immunity. J Gen Virol, 1974, 22(1): 35-41
175. Russell P H, Ezeifeka G O. The Hitchner B1 strain of Newcastle Disease virus induces high levels of IgA, IgG and IgM in newly hatched chicks. Vaccine, 1995, 13(1): 61-66
176. Russell P H. Newcastle Disease virus—virus replication in the Harderian gland stimμLates lacrimal IgA—the yolk sac provides early lacrimal IgG. Vet Immunol Immunopathol, 1993, 37(2): 151-163
177. Selleck P W, Arzey G., Kirkland P D, Reece R L., Gould A R., Daniels P W, Westbury H A. An outbreak of Highly Pathogenic Avian Influenza in Australian in 1997 Caused by an H7N4 Virus. Avian Dis, 2003, 47: 806-811.
178. Serme D A. Avian Influenza in the Western Hemisphere Including the Pacific Islands and Australia. Avian Dis, 2003, 47: 798-805
179. Seo S H, Webster R G. Cross-Reactive, Cell-Mediated Immunity and Protection of chickens from Lethal H5N1 Influenza Virus Infection in Hung Kong Poulry Markets. J Virol, 2001, 75(6): 2516-1525
180. Shimizu K,. Handa H, Nakada S,. Nagata K. Regulation of influenza virus RNA polymerase activi-ty by cellular and viral factors. Nucleic Acids Res, 1994, 22(23): 5047-5053
181. Shortridge, K. F. Avian influenza A viruses of southern China and Hong Kong: ecological aspects and implications for man. Bull World Health Organ, 1982, 60(1): 129-135
182. Slemons R D, Johnson D C, Osborn J S, Hayes F, Type-A influenza viruses isolated from wild freeflying ducks in California. Avian Dis, 1974, 18:119-124
183. Slepushkin V A, Katz J M, Black R A, Gamble W C, Rota P A, Cox N J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine, 1995, 13(15): 1399-1402
184. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, Perdue ML, Lohman K, Daum LT, Suarez DL. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol, 2002, 40(9): 3256-3260
185. Stallknecht D E. Ecology and Epidemiology of Avian Influenza Viruses in Wild Bird Populations: Waterfowl, Shorebirds, Pelicans, Cormorants, Etc. Avian Dis, 1998, 29:136-144
186. Stech J, Xiong X., Scholtissek C., Webster R G. Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. J Virol, 1999, 73(3), 1878-1884
187. Suarez D L, Schulz-Cherry S. Immunology of avian influenza virus: a review. Dev Comp Immunol, 2000, 24(2-3): 269-283
188. Suarez D L, Senne D A. The link between the live bird markets and the Pennsylvania H5N2 avian influenza outbreak of 1983-84. Avian Dis. 2000, 28: 317-322
189. Takada A, Matsushita A, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine, 2003, 21(23):3212-3218
190. Takada A, Kida H. Induction of protective antibody response against pseudorabies virus by intranasal vaccination with glycoprotein B in mice. Arch Virol, 1995, 140(9): 1629-1635
191. Takada A, Kida H. Protective immune response of chickens against Newcastle Disease, induced by the intranasal vaccination with inactivated virus. Vet Microbiol, 1996, 50(1-2): 17-25.
192. Takahashi I, Marinaro M, Kiyono H, Jackson R J, Nakagawa I, Fujihashi K, Hamada S, Clements J D, Bost K L, McGhee J R. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J infect dis, 1996, 173(3): 627-635
193. Tamura S I, Funato H, Hirabayashi Y. Function rile of respiratory tract heamagglutinin-specific IgA antibodies in protection against influenza. Vaccine, 1990, (8): 479-485
194. Tamura S I, Samegai Y, Funato H..Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccine combined with cholera toxin B subunit. Vaccine, 1989, (7): 314-323
195. Tamura S I, Samegai Y, Kurata H. Protection against influenza virus infection by vaccine inoculated intranasally with toxin B subunit. Vaccine, 1988, (6): 409-413
196. Tamura S, Ishihara K, Miyata K, Aizawa C, Kurata T. Mechanism of enchancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin. Vaccine, 1995, 13(4): 339-341
197. Tamura S, Ito Y, Asanukma H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T. Cross protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol, 1992, 146(3): 981-988
198. Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, Suzuki Y, Nagamine T, Kawabara K, Danbara H. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine, 1994, 12(5): 419-426
199. Tan S L, Katze M G. Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase, J Interferon Cytokine Res, 1998, 18(9): 757-766
200. Tochikubo K, Isaka M, Yasuda Y, Kozuka S, Matano K, Miura Y, Taniguehi T. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally coadministered bovine serum albumin. Vaccine, 1998, 16(2-3): 150-155
201. Ulmer J B, Donnelly J J, Parker S E, Rhodes G H, Felgner P L, Dwarki V J, Gromkowski S H, Deck R R, DeWitt C M, Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science, 1993, 259(5102): 1745-1746
202. Vadolas J, Davies J K, Wright P J, Strugnell R A. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur J Immunol, 1995, 25(4): 969-975
203. Vajdy M and Lycke N H. StimμLation of antigen-specific T-cell and B-cell memory in local as well as systemic lymphoid-tissues following oral immunization with cholera-toxin adjuvant. Immunology, 1993, 80(2): 197-203
204. Vajdy M and Lycke N Y. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology, 1992, 75: 488-492
205. Vajdy M, Lycke N H. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology, 1992, 75(3): 488-492
206. Van Deusen R A, Hinshaw V S, Senne D A. Micro neuraminidase-inhibition assay for classification of influenza Avirus neuraminidase. Avian Dis, 1983, 27: 745-750
207. Van Hoecke C, Comberbach M, De Grave D, Desmons P, Fu D, Hauser P, Lebacq E, Lobet Y, Voet P. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein(OspA) lyme vaccines in healthy aduls. Vaccine, 1996, 14(17-18): 1621-1626
208. Villareal C L, Flores A O. The Mexican Avian Influenza (H5N2) Outbreak. Vet Microbiol, 1997, 74: 165-172
209. Walsh E E. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine, 1993, 11(11): 1135-1138
210. Wang P, Palese P, O'Neill R. The NPI-1/NPI-3 (karyopherin a)binding site on the influenza A virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol, 1997, 71(3): 1850-1856
211. Warren H S, Vogel F R, Chedid L A. Current status of immunological adjuvants. Annu Rev Immunol, 1986, 4: 369-388
212. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol, 2002, 76(2): 767-773
213. Webster R G, Bean W J, German O T, Chambers T M, Kawaoka Y, Evolution and ecology of influenza A viruses. Microbiol Rev, 1992, 56(1): 152-179
214. Webster R G, Bean W J, German O T, Chambers T M, Kawaoka Y. Evolution and Ecology of influenza A viruses. Microbiol Rev, 1992, 56(1): 152-157
215. Webster R G, Laver W G, Air G M, Schild G C. Molecular mechanisms of variation in influenza viruses. Nature, 1982, 296(5853): 115-121
216. Westbury H A. History of Highly Pathogenic Avian Influenza in Australia. In: Proceedings of the 4th International Symposium on Avian Influenza, Athens, Georgia. US Animal Health Association, 1998, 23-30
217. Wiley D C, Wilson I A, Skehel J J. Structural identification of the antibody-binding sites of Hong Kong influenza haemaggiutinin and their involvement in antigenic variation. Nature, 1981, 289(5796): 373-378
218. Wilson A D, Clarke C J, Stokes C R. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol, 1990, 31(4): 443-451
219. Wilson A D, Robinson A, Irons L, Stokes C R. Adjuvant action of cholera-toxin and pertussis toxin in the induction of IgA antibody-response to orally administered antigen. Vaccine, 1993, 11(2): 113-118
220. Wu H Y and Russell M W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine, 1998, 16(2-3): 286-292
221. Wu H Y and Russell M W. Induction of Mucosal Immunity by Intranasal Application of a Streptococcal Surface Protein Antigen with the Cholera Toxin B Subunit. Infect Immun, 1993, 61(1): 314-322
222. Yewdell J W, Bennink J R, Smith G L, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA, 1985, 82(6): 1785-1789
223. Yuen K Y, Chan P K, Peiris M, Tsang D N, Que T L, Shortridge K F, Cheung P. T, To W K, Ho E T F, Sung R, Cheng A F. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351(9101): 467-471
224. Zebedee S L and Lamb R A. Influenza A virus M2 protein monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol, 1988, 62(8): 2762-2772
2.于康震,陈化兰,唐秀英.97香港禽流感.中国畜禽传染病,1998,20(3):187-191
3.于康震,崔尚金,付朝阳,唐秀英.禽流感与养禽业发展和人类健康.中国预防兽医学报,2000,22(4):312-315
4.马保华和毕英佐.IgA与粘膜免疫.辽宁畜牧兽医,1999,1:40-42
5.马思奇.粘膜免疫与未来的疫苗发展.中国畜禽传染病,1994,5:55-57
6.王恒安,王士强,严亚贤,吴祖立,华修国.鸭源禽流感病毒的分离与鉴定.江苏农业研究,1999,20(4):57-60
7.王锡坤,鞠复帮,王立南.禽流感琼脂扩散试验抗原制备方法的研究.中国畜禽传染病,1987,7(1):24-26
8.邓国华,唐秀英,田国斌.禽流感病毒重组核蛋白在琼扩诊断中的应用.中国预防兽医学报,2000,22(增刊):25-27
9.付朝阳,邢大昌,唐秀英,张亚非,于康震,冯菊艳.高致病力禽流感的流行与防制研究进展.中国预防兽医学报,2001,23(5):393-396
10.付朝阳,于康震,唐秀英,贾永清,冯菊艳,田国斌,吴东来.H9亚型禽流感油乳剂灭活苗免疫产生期内T淋巴细胞表型亚类的检测与研究.中国预防兽医学报,2001,23(6):430-433
11.甘孟侯主编.禽流感.北京:北京农业大学出版社,1995
12.甘孟侯主编.禽流感.第二版,北京:中国农业出版社,2002.
13.田国斌,赵增连,唐秀英,林祥梅,于康震,陈溥言.鸭源禽流感病毒的分离和鉴定.中国预防兽医学报,1999,21(1):1-3
14.田季德,徐兆炜,高庆申,刘延清.霍乱毒素B亚单位基因的克隆和表达.中国医学科学院学报,1991,13(5):332-337
15.石成华,曹诚,张京生,马清均.乙肝PreS2抗原决定簇和霍乱毒素B亚单位因的融合与表达.生物化学杂志,1994,10(5):533-538
16.刘明,于康震,崔尚金.RT-PCR快速诊断禽流感的研究.中国预防兽医学报,2000,22(增刊):176-179
17.刘泽文,徐涤平,杨峻,邵华斌,段正赢,山口成夫.应用逆转录套式PER检测禽流感病毒核酸研究.湖北农业科学,2003,4:90-92
18.朱立平,陈学清主编.免疫学常用实验方法.北京:人民军医出版社,2000
19.纪剑飞,张成刚.包涵体重组蛋白的纯化及复性,沈阳药科大学学报,1998,15(4):303-307
20.阴天榜,刘兴友等著.家禽免疫学.北京:中国农业出版社,1999
21.何志勇,李明峰,张惟杰,吴祥甫.霍乱毒素B亚单位基因(CtxB)的克隆及其表达.生物化学与生物物理学报,2000,32(2):149-152
22.何昭阳,胡桂学,王春风主编.动物免疫学实验技术.长春:吉林科学技术出版社,2002,59-61。
23.宋晓晖,王中力,陈西钊.禽流感诊断研究进展.中国动物检疫,2003,20(11):45-47
24.张庶民,祁自柏.基因工程表达蛋白包涵体的形成和纯化.微生物学免疫学进展,1995,23(1):52-54
25.张鹤晓,赖平安,刘环,刘继红,郭晋优,谷强,张利峰,汪琳,段生涛,朱文斯,杨伟,黄茜华,赖少梅,李宁.荧光RT-PCR方法检测活禽和禽组织中禽流感病毒的研究.检验检疫科学,2004,14(1):1-5
26.李自力,许青荣,毕丁仁,王桂枝,程峰.湖北省禽流感的诊断及病毒株的分离与初步鉴定中国预防兽医学报,2001,23(3):146-148
27.李海燕,于康震,辛晓光,秦运安,李雁冰.禽流感间接ELISA诊断试剂盒的研制及应用.中国预防兽医学报,2001,2(35):372-376
28.李海燕,辛晓光,田国斌,张晶,于康震.禽流感抗体斑点-ELISA诊断诊断技术的研究.中国预防兽医学报,1999,21(5):321-325
29.李海燕,辛晓光.禽流感病毒抗原成分免疫活性的分布研究.中国预防兽医学报,2000,22(增刊):94-97
30.杜念兴主编.兽医免疫学,第二版.北京:中国农业出版社,1997
31.沈关心,周汝麟主编.现代免疫学实验技术.武汉:湖北科学技术出版社,1998
32.肖运才,李自力,胡思顺,石德时,许青荣,程峰,刘梅,毕丁仁,王桂枝.禽流感病毒夹心ELISA快速检测方法的研究.畜牧兽医学报,2004,35(5):536-541
33.邱德新.猪繁殖与呼吸综合征(PRRS)和伪狂犬病ELISA抗体检测方法及PRRSV弱毒活疫苗研究.[博士论文].华中农业大学,2003
34.陈化兰,于康震,田国滨,唐秀英,卢景良.DNA免疫诱导鸡对禽流感病毒的免疫保护反应.中国农业科学,1998,31(5):63-68
35.陈化兰,于康震,田国滨,唐秀英,卢景良.禽流感病毒血凝素基因的克隆及其DNA疫苗的免疫原性.中国兽医学报,1997,17(6):555-558
36.陈化兰,于康震,张建林,田国彬,唐秀英.H7亚型禽流感病毒血凝素基因重组鸡痘病毒活载体疫苗免疫原性评估.中国预防兽医学报,2004,26(1):7-9
37.陈全娇.鸡源禽流感的分离鉴定及HA基因的克隆和表达.[硕士论文].华中农业大学,2003
38.陈吉祥,李广林,薛飞群,陈化兰,于康震,赵荣材.禽流感HA基因疫苗脂质体的制备及其理化性质,中国兽医学报,1999,19(3):230-232
39.陈伯伦,张泽纪,陈伟斌.禽流感研究Ⅰ.鸡A型禽流感病毒的分离和血清学初步鉴定.中国兽医杂志,1994,20(10):3-5
40.陈伯伦,张泽纪,陈伟斌.禽流感研究Ⅰ.鸡A型禽流感病毒的分离和血清学初步鉴定.中国兽医杂志,1994,20(10):3-5
41.陈绍熙,阚立抒,孙广力,赵春泰,邢秀珍,车有权.黑龙江省禽流感调查.中国畜禽传染病,1997,4:56-57
42.陈福勇,夏春.禽流感A/鸡/北京/1/96(H9N2)株核蛋白基因克隆和序列分析.中国预防兽医学报,1999,21(2):130-133
43.周元军.禽流感的防制与禽流感监测系统的建立.医学动物防制,2003,19(5):311-313
44.林纪胜.粘膜免疫的研究进展.中国人兽共患病杂志,1999,15(4):86-88
45.金奇主编.医学分子病毒学.北京:科学出版社,2001
46.柯岩,陈哲生.制各兔抗人IgG抗体的一种简便方法.微生物学通报.1997,24(5):315—317
47.赵增连,陈溥言,林祥梅,蔡宝祥.一种敏感的禽流感病毒快速定型双扩散法.中国兽医学报,1997,17(3):290-291
48.饶吉航,冉智光,苏承忠,蒋茹,胡友兰,汤明.鹌鹑H93亚型禽流感.中国兽医医杂,2004,40(2):56
49.凌明圣,许祥裕,丁树标.以包涵体形式存在的重组蛋白的纯化和体外折叠.中国生化药物杂志,1995,16(3):135-138
50.唐秀英,田国斌,于康震,冯菊艳.禽流感油乳剂灭活疫苗的研究.中国预防兽医学报,1999,21(6):401-405
51.唐秀英,田国斌,赵传删,周金法,于康震.中国禽流感流行株的分离鉴定.中国畜禽传染病,1998,20(1):1-5
52.唐建霞,王幼明,黄克和.实验性感染禽流感病毒抑制鸡的细胞免疫功能.江苏农业科学,2004(1):75-77
53.徐玉栋.粘膜DNA疫苗研究进展.国外医学口腔医学分册,2000,27(5):283-285
54.殷震,刘景华主编.动物病毒学.第二版.北京:科学出版社,1997
55.郭志儒和高宏伟.我国应尽快建立兽医与人医一体化的公共卫生体系.中国兽医学报,2004,24(3):209-211
56.郭建刚,李华明,刘棋,邹联斌,郑敏,邓朝阳.五种常用消毒剂对禽流感病毒的杀灭试验.广西畜牧兽医,2003,19(2):63-64
57.郭春祥和郭锡琼.介绍一种简单、快速、高效的辣根过氧化物酶标记抗体的过碘酸钠法.上海免疫学杂志,1983,3(2):97-100
58.顾云,张莉,大野尚仁.鼠和兔中流行性感冒病毒抗体的制备及测定.药物生物技术,2003,10(2):106
59.顾贫.区分口蹄疫免疫动物与野毒感染动物的鉴别诊断方法研究.[博士论文].华中农业大学,2003
60.高杰英.粘膜免疫向免疫学提出了新问题.上海免疫学杂志,2000,20(5):257-259
61.高致病性禽流感防治手册编写组编.高致病性禽流感防治手册.北京:中国农业出版社,2004:7-8
62.崔尚金,陈化兰,唐秀英,邓国华,田国斌,于康震.禽流感RT-PCR诊断法的建立.中国畜禽传染病,1998,20(2):105-107。
63.曹诚,马清均,石成华等.丙型肝炎病毒抗原决定簇与霍乱毒素B亚单位的融合表达及融合蛋白的抗原性.病毒学报,1995,11(2):99-106
64.黄庚明,辛朝安.PCR制备地高辛标记的探针检测禽流感病毒核酸.中国兽医杂志,2001,37(12):3-7
65.黄祯祥.医学病毒学基础及实验技术.北京:科学出版社,1990,661-671
66. Abraham A, Sivanandan V, Haivorson A, et al.. Standardization of enzyme-linked immunosorbent assay for avian influenza virus antibodies in turkeys. Am J Vet Res, 1986, 47(3): 561-566
67. Abraham A,Sivanandan V et al. Antigen-capture enzyme immunoassay for detection of avian influenza virus in turkeys. Am J Vet Res, 1993, 54(9): 1385-1390
68. Aitken R, Hirst T R, Recombinant enterotoxins as vaccine against Escherichia coli-mediated diarrhoea, Vaceine, 1993, 11: 227-233
69. Alexander D J, Lister S A,. Johnson M J, Randall C J, Thomas P J. An outbreak of highly pathogenic avian influenza in turkeys in Great Britain in 1991. Vet Rec, 1993, 132:535-536
70. Alexander D J. Current Situation of Avian Influenza in Poulry in Great Britain.. Proc. first International Symposium on Avian Influenza, 1986, 35-45.
71. Alexander D J. Report on Avian Influenza in the Eastern Hemisphere during 1997-2002. Avian Dis, 2003, 47:792-797
72. Bean W J. Correlation of influenza A virus nucleoprotein genes with host species. Hrology, 1984, 133(2): 438-442.
73. Beard C W. Avian influenza antibody detection by immunodissusion. Avian Dis, 1970, 14 (2):337-341
74. Bennink J R and Yewdell J W. Mttrine eytotoxic T lymphocyte recognition of individual influen-za virus proteins. High frequency of nonresponder MHC class Ⅰ alleles, J Exp Med, 1988, 168:1935—1939.
75. Beunink J R, Yewdell J W, Gerhard W. A viral polymerase involved in recognition of influenza virus-infected cells by a cytotoxie T-cell clone. Nature, 1982. 296:75—76.
76. Bennink J R, Yewdell J W, Smith G L, Moss B. Anti-influertzavirus cytotoxie T lymphocytes re-cognize the three viral polymerases and a nonstruetural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. J Virol, 1987, 61:1098-1102
77. Biswas S K., Boutz P, Nayak D P. Influenza Virus Nucleoprotein Interacts with Influenza Virus Polymerase Proteins. J Virol, 1998, 72(7): 5493-5501
78. Blanehard T G, Lycke N,. Czinn S J, Nedrud J G. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 1998, 93:22-27
79. Boyle D B, Selleck P, Heine H G. Vaccinating chickens against avian influenza with fowlpox recombinants expression the H7 haemagglutinin. Aust Vet J, 2000,78 (1): 44-48
80. Brown E G. Influenza virus genetics. Biomed & Pharmacother, 2000. 54:196-209
81. Buisch WW, Hall AE, Mcdaniel HA. 1985-1984 lethal avian influenza outbreak. Virology,1984, 146:963-973
82. Butler J E, Richardson H B, Swanson P A, Kopp W C, Suelzer M T. The influence of muramyl peptide on the secretory immune response. Annals of the New York Academy of science, 1983, 409:669-687
83.CalnekB W主编.高福,苏敬良主译.禽病学第十版,中国农业出版社,1999
84. Carnpen H, Easterday B C, Hinshaw V S, Van-Campen H. Destruction of lymphocytes by a virμLent avian influenza A virus. J Gen Virol, 1989a, 70:467-472
85. Campen H, Easterday B C, Hinshaw V S, Van-Campen H. Virulent avian influenza A viruses: their effect on avian lymphocytes and macrophages in vivo and in vitro. J Gen Virol, 1989b, 70: 2887-2895
86. Capua I, Alexander D J. Avian influenza and human health. Acta Trop, 2002, 83(1): 1-6
87. Chen Z, Li Y, Krug R M. Influenza A virus NSI protein targets poly(A)-binding protein Ⅱ of the cellar 3'-end processing machinery. EMBO J, 1999, 18:2273-2283
88. Christensen J P, Doherty P C, Branum K C, Riberdy J M. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8~+T cell memory. J Virol, 2000, 74:11690-11696
89. Claas E C J, de Jong J C, van Beck R. Human influenza virus A/Hongkong/156/97(H_5N_1 infection. Vaccine, 1998, 16(9/10): 977-978
90. Cleland J L and Wang D I C. Cosolvent effects on refolding and ggregation. ASC Syymposium Ser, 1993, 516:151-166
91. Clements J D, Hartxog N M, Lynon F L. Adjuvant activity of Escheriehia eoli heat labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine, 1988, 6:269-277
92. Czerkinsky C, Russell M W. Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun, 1989, 57(4): 1072-1077
93. Dallas W S and Falkow S. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin. Nature, 1980, 288(5790): 499-501
94. Davey J, Dimmock N J, Colman A. Identification of the sequence responsible for the nuclear accumulation of the influenza virus nucleoprotein in Xenopns oocytes. Cell, 1985, 40 (3): 667-675.
95. de Geus B, Dol-Bosman M, Seholten J W, Stok W, Bianchi A. A comparison of natural and recombinant cholera toxin B subunit as stimμLatoryfactors in intranasal immunization. Vaccine, 1997, 15(10): 1110-1113
96. de Haan L, Verweij W R, Felt I K, Holtrop M, Hol W G J, Agsteribbe E, Wilsehut J. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology, 1998, 94(3): 424-430.
97. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun, 1997, 65(7): 2821-2828.
98. Dubenskey T W Jr, Liu M H ,ulmer J B. Delivery systems for gene-based vaccines. Mol Med, 2000,6(9): 723-732.
99. Elson C O, Ealding W. Generalised systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol, 1984, 132(6): 2736-2741
100. Erdile L F, Guy B. OspA lipoprotein of Borrelia burgdofferi is a mueosal immunogen and adjuvant. Vaccine, 1997, 15(9): 988-996
101. Fitch W M, Leiter J M, Li X Q, Palese P. Positive Darwinian evolution in human influenza A vi- ruses. Prec. Natl. Acad. Sci. USA, 1991, 88(10): 4270-4274.
102. Flo J, Goldman H, Roux M, Massouh E. Oral administration era bacterial immunomodulator enhances the immune response to cholera toxin. Vaccine, 1996, 14(12): 1167-1173
103. Frace A M, Klimov A I, Rowe T, Black R A, Katz J M. Modified M2 proteins produce heretotypic immunity against influenza A virus. Vaccine, 1999, 17:2237-2244.
104. Fukushima A, Yoo Y C, Yoshimatsu K, Matsuzawa K, Tamura M, Tono-oka S, Taniguchi K, Urasawa S, Arikawa J, Azuma I. Effect of MDP-LYS(L18)as a mueosal immtmoadjuvant on protection of mucosal infection by Sendai virus and rotavirus. Vaccine, 1996, 14(6): 485-491
105. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy D E, Durbin J E, Palese P, Muster T. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems, Virology, 1998, 252(2): 324-330
106. Garnett W H. Status of avian influenza in poulry: 1981-1986. In: Proceedings of the Second International Symposium on Avian influenza, 1987. University of Wisconsin, Madison, pp. 61-66.
107. Gelb J Jr, Nix W A, Gellman S D. Infectious bronchitis virus antibodies in tears and their relationship to immunity. Avian Dis, 1998, 42(2): 364-374
108. Gleeson M, Pyne D B. Exercise effects on mucosal immunity. Immunology and Cell Biology, 2000, 78:536-544
109. Gotch F, MeMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human eytotoxic T lymphocytes. J Exp Med, 1987,165(2):408-416
110. Gust I D, Hampson A W, Lavanchy D. Planning for the next pandemic of influenza. Rev Med Virol, 2001, 11(1): 59-70
111. Hajishengallis G, Hollingshead S K, Koga T, Russell M W. Mueosal Immunization with a Bacterial Protein Antigen genetically coupled to cholera toxin A2/B subunit. J Immun, 1995, 154(9): 4322-4332
112. Hannant D, Easeman R. I, Mumford J A. Mucosal vaccination with inactivated equine influenza virus stimulates neutralising antibody in that nasopharynx of horses. Vet Immunol Immunopathol, 1996, 54(3): 205-209
113. Hatada E, Saito S, Fukuda R. Mutant influenza viruses with a defective NS1 protein cannot bock the activation of PKR in infected cells. J Virol, 1999, 73(3): 2425-2433
114. Hayashida H, Toh H, Kikuno R, Miyata T. Evolution of influenza genes. Mol Biol Evol, 1985, 2(4): 289-303
115. Hazama M, Mayumi-Aono A, Miyazaki T, Hinuma S, Fujisawa Y. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, and B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology, 1993, 78(4): 643-649
116. Hinshaw V S, Olsen C W, Dybdahl-sissoko N, Evans D. Apoptosis: a mechanism of cell killing by influenza A and B viruses. J Virol,1994, 68(6): 3667-3673
117. Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature, 1981, 292(5822): 413-417
118. Inn H B. The epidemiology and evolution of influenza viruses in pigs. Vet Microbiol, 2000, 74(1-2): 29-46
119. Itakura K, Hirose T, Crea R, Riggs A D, Heynecker H, Bolivar F, Boyer H W. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin, Science, 1977, 198(4321): 1056-1063
120. Ito T, Gorman O T, Kawaoka Y, Bean W J, Webster R G, Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins, J Virol, 1991,65(10): 5491-5498.
121. Jameson J, Cruz J,. Ennis F A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol, 1998, 72(11): 8682-8689
122. Jayawardane G W L, Spradbrow P B. Mueosal immunity in chickens vaccinated with the V4 strain of Newcastle Disease virus. Vet Microbiol, 1995, 46(1-3): 69-77.
123. Johansson B E, Bucher D J, Kilbourne E D. Purified influenza virus hemagglutinin and neuramin- idase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol, 1989, 63(3): 1239-1246
124. Kawaoka Y, Chambers T M, Sladen W L, Webster R G, Is the gene pool of influenza viruses in shorebirds and gμLls different from that in wild ducks? Virology, 1988, 163(1): 247-250
125. Kawaoka Y, Gorman O T, Ito T, Wells K, Donis R O, Castmeei M R, Donatelli I, Webster R G.. Influence of host species on the evolution of the nonstmetural (NS) gene of influenza A viruses. Virus Res, 1998, 55(2): 143-156
126. Keller D, Koster F T, Marks D H, Hosbach P, Erdile L F, Mays J P. Safety and immunogenicity of a recombinant outer surface protein A lyme vaccine, JAMA, 1994, 271 (22): 1764-1768
127. Kodihaili S, Sivanandau V, Nagaraja K V, Shaw D, Halvorson DA. A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection. Vaccine, 1994,12(15): 1467-1472
128. Kodihaili S, Sivanandan V, Nagaraja KV, Goyal SM, Halvorson DA. Antigen-capture enzyme immunoassay for detection of avian influenza virus in turkeys. Am J Vet Res, 1993, 54(9): 1385-1390
129. Kuwano K, Scott M, Young J F, Ennis F A. HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response. J Immunol, 1988. 140(4):1264-1268
130. Kuwano K, Tamura M, Ennis F A. Cross-reactive protection against influenza A virus infections by an NSl-specifie CTL clone. Virology, 1990, 178(1): 174-179.
131. Lasley F A. Economies Of Avian Influenza: Control vs Noncontrol. In: Proceedings of the Second International Symposium on Avian Influenza, 1987. University of Wisconsin, Madison, pp.390-399.
132. Laudert E, Sivanandan V, Haivorson D. Effect of an H5Nlavian influenza virus infection on the immune system of mallard ducks. Avian Dis, 1993, 37(3): 845-850
133. Lee A and Chen M. Successful immunization against gastric infection with Helicobacter species: use era cholera toxin B-subunit-whole-cell vaccine, Infect Immun, 1994, 62(8): 3594-3597.
134. Levi R ,Amen R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine, 1996,14(1): 85-92.
135. Liang X P, Lamm M E, Nedrud J G.. Oral administration of cholera toxin-sendai virus conjugate potentiates gut and respiratory immunity against sendai virus. J Immunol, 1988, 141(5): 1495-1501
136. Lipscombe M, Charles I G, Roberts M, Dougan G, Tite J, Fairweather N F. Intranasal immunization using the B subunit of Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertusis P.69 antigen. Mol Microbiol, 1991.5(6): 1385-1392
137. Liu L M and MacPherson G G.. Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and prime naive T cells in rive. J Exp Med, 1993, 177(5): 1299-1305
138. Lovgren K, Kaberg H, Morein B. An experimental influenza subunit vaccine(iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous adminitration. Clin Exp Immunol, 1990, 82(3): 435-439
139. Lovgren K. the serum antibody response diatributed in subclass and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol, 1988, 27(2): 241-245
140. Lycke N and Hoimgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology, 1986, 59(2): 301-308
141. McGhee J R, Mestecky J, Dertzbaugh M T, Eldridge J H, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development.Vaccine, 1992, 10(2): 75-88
142. MeKENZIE S J and Halsey J F. Cholera Toxin B subunit As a Carrier Protein to Stimulate a Mucosal Immune Response. J Immunol, 1984, 133(4): 1818-1824
143. McNuly M S, Allan G M, Adair B M. Efficacy of avian influenza neuraminidase -specific vaccines in chickens. Avian Pathol, 1986, 15:107-115
144. Mestecky J. The common mucosal immune system and current strategies for induction of immune response in external secretions. J Clin Immunol, 1987, 7(4): 265-272
145. Michalek S M,Morisaki I, Gregory R I, Kiyono H,Hamada S,MeGhee J R . Oral adjuvant enhance IgA responses to Streptococcus rautans. Mol Immunol, 1983, 20(9): 1009-1018
146. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 1984, 308(5958): 457-460
147. Morein B. Iscoms. VetMicrobiol, 1990, 23(1-4): 79-84
148. Morein B.The iscom antigen-presenting system. Nature, 1988, 332(6161): 287-288
149. Morisaki I,Michalek S M, Harmon C C,Terii M, Hamada S, McGhee J R. Effective immunity to dental caries:enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants. Infect Immun, 1983, 40(2): 577-591
150. Mowat A M, Donaclaie A M, Reid G, Jarrett O. Immune-stimulating complexes containing QuilA and protein antigen prime class Ⅰ MHC-restrieted T lymphoeytes in vivo and are immunogenic by the oral route. Immunology, 1991, 72(3): 317-322
151. Mowat A M, Maloy K J, Donachie A M. Immune-stimμLating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology, 1993, 80: 527-534.
152. Murphy F A, Paul J, Marian C, Veterinary Virology (Third edition). Academic Press, New York, 1999, 459-468
153. Naeem K. The avian in(?)uenza H7N3 outbreak in South Central Asia. In: Proceedings of the 4th International Symposium on Avian Influenza, Athens, Georgia. US Animal Health Association, 1998, pp, 31-35
154. Nashar T O, Amin T, Mareello A, Hirst T R. Current progress in the development of the b-subunits of cholera-toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine, 1993.11 (2): 235-240
155. Nedrud J G, Liang X, Hague N, Lamm M E. Combined oral/nasal immunization protects mice from sendal virus infection. J Immunol,1987, 139(10): 3484-3492
156. Neirynek S, Derro T, Saelens X, et al. A universal influenza A vaccine based on the extraeellular domain of the M2 protein. Nat Med,1999,5(10): 1157-1163
157. Nemeroff M E, Barabino S M, Li Y, Keller W, Krug R M. Influenza virus NS1 protein interacts with the cellar 30 kDa subunit of CPSF and inhibits 3'-end formation of cellular pre-mRNAs. Mol Cell, 1998, 1(7): 991-1000
158. Neumann G, Castrucci M R, Kawaoka Y. Nuclear Import and Export of Influenza Virus Nucleoprotein. J Virol, 1997,71(12): 9690-9700
159. Nicholoson K G, Wood J M, Zambon M. Influenza. Lancet, 2003, 362(9397): 1733-1745
160. Nugent J, A Li Wan Po, Scott E M. Design and delivery of non-parenteral vaccines. J Clin Pharm Ther, 1998, 23(4): 257-285
161. O'Neill R E, Talon J, Palese P. The influenza virus NEP(NS2 protein)mediates the nuclear export of viral ribonucleoproteins. EMBO J, 1998, 17(1): 288-296
162. Ogra P, Leibovitz E, Zhao-Ri G. Oral immunization and secretory immunity to virus. Curr Top Microbiol Immunol, 1989, 146:73-81
163. Oka T, Honda T, Morokuma R, Ginnaga A, Ohkuma K, Sakoh M. Enhancing effects of pertusis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally. Vaccine, 1994, 12(14): 1255-1258
164. Parkin N ,Chiu P ,Coelingh K. Genetically engineered live attenuated influenza A virus vaccine candidates. J Virol, 1997, 71(4): 2772-2778
165. Parvin J D, Moscona A, Pan W T, Leider J M, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol, 1986, 59(2): 377-383.
166. Pavlovskis O R, Rollwagen F M, Rollins D M, Walker R I. Experimental oral camplyobacter vaeine. Vaccine, 1992, 10:290-295
167. Pertmer T M, Oran A E, Moser J M, Madorin C A, Robinson H L. DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nueleoprotein. J Virol, 2000, 74:7787-7793.
168. Philpott M, Easterday B C, Hinshaw V S. Neutralizing epitopes of the H5 hemagglutinin from a virulent avian influenza virus and their relationship to pathogenicity. J Virol, 1989, 63: 3453-3458
169. Qiao C L, Yu K Z ,Jiang Y P, Jia Y Q, Tian G B, Liu M, Deng G H, Wang X R, Meng Q W, Tang X Y. Protection of chickens against highlt lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol, 2003,32(1): 25-32.
170. Reay P A, Jones I M, Gotch F M, McMichael A J, Brownlee G G. Recognition of the PBI, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxie T lymphocytes. Virology, 1989, 170:477-485
171. Robert J, Eekroade D V M, Linda A. Avian Influenza in Pennsylvania—The Beginning. In: Proceedings of the Second International Symposium on Avian Influenza, University of Wisconsin, Madison, 1987, pp. 22-32
172. Rogers G N. and PaμLson J C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology, 1983, 127(2): 361-373
173. Rollwagen F M, Pacheco N D, Clements J D, Pavlovskis O R, Rollins D M, Walker R I. Killed campylobacter elicits immune-response and protection when administered with an oral adjuvant. Vaccine, 1993, 11(13): 1316-1320
174. Rott R, Becht H, Orlich M. The significance of influenza virus neuraminidase in immunity. J Gen Virol, 1974, 22(1): 35-41
175. Russell P H, Ezeifeka G O. The Hitchner B1 strain of Newcastle Disease virus induces high levels of IgA, IgG and IgM in newly hatched chicks. Vaccine, 1995, 13(1): 61-66
176. Russell P H. Newcastle Disease virus—virus replication in the Harderian gland stimμLates lacrimal IgA—the yolk sac provides early lacrimal IgG. Vet Immunol Immunopathol, 1993, 37(2): 151-163
177. Selleck P W, Arzey G., Kirkland P D, Reece R L., Gould A R., Daniels P W, Westbury H A. An outbreak of Highly Pathogenic Avian Influenza in Australian in 1997 Caused by an H7N4 Virus. Avian Dis, 2003, 47: 806-811.
178. Serme D A. Avian Influenza in the Western Hemisphere Including the Pacific Islands and Australia. Avian Dis, 2003, 47: 798-805
179. Seo S H, Webster R G. Cross-Reactive, Cell-Mediated Immunity and Protection of chickens from Lethal H5N1 Influenza Virus Infection in Hung Kong Poulry Markets. J Virol, 2001, 75(6): 2516-1525
180. Shimizu K,. Handa H, Nakada S,. Nagata K. Regulation of influenza virus RNA polymerase activi-ty by cellular and viral factors. Nucleic Acids Res, 1994, 22(23): 5047-5053
181. Shortridge, K. F. Avian influenza A viruses of southern China and Hong Kong: ecological aspects and implications for man. Bull World Health Organ, 1982, 60(1): 129-135
182. Slemons R D, Johnson D C, Osborn J S, Hayes F, Type-A influenza viruses isolated from wild freeflying ducks in California. Avian Dis, 1974, 18:119-124
183. Slepushkin V A, Katz J M, Black R A, Gamble W C, Rota P A, Cox N J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine, 1995, 13(15): 1399-1402
184. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, Perdue ML, Lohman K, Daum LT, Suarez DL. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol, 2002, 40(9): 3256-3260
185. Stallknecht D E. Ecology and Epidemiology of Avian Influenza Viruses in Wild Bird Populations: Waterfowl, Shorebirds, Pelicans, Cormorants, Etc. Avian Dis, 1998, 29:136-144
186. Stech J, Xiong X., Scholtissek C., Webster R G. Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. J Virol, 1999, 73(3), 1878-1884
187. Suarez D L, Schulz-Cherry S. Immunology of avian influenza virus: a review. Dev Comp Immunol, 2000, 24(2-3): 269-283
188. Suarez D L, Senne D A. The link between the live bird markets and the Pennsylvania H5N2 avian influenza outbreak of 1983-84. Avian Dis. 2000, 28: 317-322
189. Takada A, Matsushita A, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine, 2003, 21(23):3212-3218
190. Takada A, Kida H. Induction of protective antibody response against pseudorabies virus by intranasal vaccination with glycoprotein B in mice. Arch Virol, 1995, 140(9): 1629-1635
191. Takada A, Kida H. Protective immune response of chickens against Newcastle Disease, induced by the intranasal vaccination with inactivated virus. Vet Microbiol, 1996, 50(1-2): 17-25.
192. Takahashi I, Marinaro M, Kiyono H, Jackson R J, Nakagawa I, Fujihashi K, Hamada S, Clements J D, Bost K L, McGhee J R. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J infect dis, 1996, 173(3): 627-635
193. Tamura S I, Funato H, Hirabayashi Y. Function rile of respiratory tract heamagglutinin-specific IgA antibodies in protection against influenza. Vaccine, 1990, (8): 479-485
194. Tamura S I, Samegai Y, Funato H..Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccine combined with cholera toxin B subunit. Vaccine, 1989, (7): 314-323
195. Tamura S I, Samegai Y, Kurata H. Protection against influenza virus infection by vaccine inoculated intranasally with toxin B subunit. Vaccine, 1988, (6): 409-413
196. Tamura S, Ishihara K, Miyata K, Aizawa C, Kurata T. Mechanism of enchancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin. Vaccine, 1995, 13(4): 339-341
197. Tamura S, Ito Y, Asanukma H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T. Cross protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol, 1992, 146(3): 981-988
198. Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, Suzuki Y, Nagamine T, Kawabara K, Danbara H. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine, 1994, 12(5): 419-426
199. Tan S L, Katze M G. Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase, J Interferon Cytokine Res, 1998, 18(9): 757-766
200. Tochikubo K, Isaka M, Yasuda Y, Kozuka S, Matano K, Miura Y, Taniguehi T. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally coadministered bovine serum albumin. Vaccine, 1998, 16(2-3): 150-155
201. Ulmer J B, Donnelly J J, Parker S E, Rhodes G H, Felgner P L, Dwarki V J, Gromkowski S H, Deck R R, DeWitt C M, Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science, 1993, 259(5102): 1745-1746
202. Vadolas J, Davies J K, Wright P J, Strugnell R A. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur J Immunol, 1995, 25(4): 969-975
203. Vajdy M and Lycke N H. StimμLation of antigen-specific T-cell and B-cell memory in local as well as systemic lymphoid-tissues following oral immunization with cholera-toxin adjuvant. Immunology, 1993, 80(2): 197-203
204. Vajdy M and Lycke N Y. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology, 1992, 75: 488-492
205. Vajdy M, Lycke N H. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology, 1992, 75(3): 488-492
206. Van Deusen R A, Hinshaw V S, Senne D A. Micro neuraminidase-inhibition assay for classification of influenza Avirus neuraminidase. Avian Dis, 1983, 27: 745-750
207. Van Hoecke C, Comberbach M, De Grave D, Desmons P, Fu D, Hauser P, Lebacq E, Lobet Y, Voet P. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein(OspA) lyme vaccines in healthy aduls. Vaccine, 1996, 14(17-18): 1621-1626
208. Villareal C L, Flores A O. The Mexican Avian Influenza (H5N2) Outbreak. Vet Microbiol, 1997, 74: 165-172
209. Walsh E E. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine, 1993, 11(11): 1135-1138
210. Wang P, Palese P, O'Neill R. The NPI-1/NPI-3 (karyopherin a)binding site on the influenza A virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol, 1997, 71(3): 1850-1856
211. Warren H S, Vogel F R, Chedid L A. Current status of immunological adjuvants. Annu Rev Immunol, 1986, 4: 369-388
212. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol, 2002, 76(2): 767-773
213. Webster R G, Bean W J, German O T, Chambers T M, Kawaoka Y, Evolution and ecology of influenza A viruses. Microbiol Rev, 1992, 56(1): 152-179
214. Webster R G, Bean W J, German O T, Chambers T M, Kawaoka Y. Evolution and Ecology of influenza A viruses. Microbiol Rev, 1992, 56(1): 152-157
215. Webster R G, Laver W G, Air G M, Schild G C. Molecular mechanisms of variation in influenza viruses. Nature, 1982, 296(5853): 115-121
216. Westbury H A. History of Highly Pathogenic Avian Influenza in Australia. In: Proceedings of the 4th International Symposium on Avian Influenza, Athens, Georgia. US Animal Health Association, 1998, 23-30
217. Wiley D C, Wilson I A, Skehel J J. Structural identification of the antibody-binding sites of Hong Kong influenza haemaggiutinin and their involvement in antigenic variation. Nature, 1981, 289(5796): 373-378
218. Wilson A D, Clarke C J, Stokes C R. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol, 1990, 31(4): 443-451
219. Wilson A D, Robinson A, Irons L, Stokes C R. Adjuvant action of cholera-toxin and pertussis toxin in the induction of IgA antibody-response to orally administered antigen. Vaccine, 1993, 11(2): 113-118
220. Wu H Y and Russell M W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine, 1998, 16(2-3): 286-292
221. Wu H Y and Russell M W. Induction of Mucosal Immunity by Intranasal Application of a Streptococcal Surface Protein Antigen with the Cholera Toxin B Subunit. Infect Immun, 1993, 61(1): 314-322
222. Yewdell J W, Bennink J R, Smith G L, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA, 1985, 82(6): 1785-1789
223. Yuen K Y, Chan P K, Peiris M, Tsang D N, Que T L, Shortridge K F, Cheung P. T, To W K, Ho E T F, Sung R, Cheng A F. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351(9101): 467-471
224. Zebedee S L and Lamb R A. Influenza A virus M2 protein monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol, 1988, 62(8): 2762-2772